Vol 7, No 3 (2021)
Review paper
Published online: 2021-09-30
Page views 4859
Article views/downloads 63
Get Citation

Connect on Social Media

Connect on Social Media

A graphical guide on adalimumab treatment in outpatient clinic: a patient with psoriasis

Aleksandra Lesiak1, Joanna Narbutt1, Agnieszka Owczarczyk-Saczonek2, Witold Owczarek3, Adam Reich4, Lidia Rudnicka5, Jacek Szepietowski6, Irena Walecka7, Julia Feldman8
Forum Dermatologicum 2021;7(3):61-67.

Abstract

According to the guidelines of Polish Dermatological Society biological drugs from TNF-alpha inhibitor group (including adalimumab) should not be treated as innovative drugs but as a therapeutic standard, which results from many years of experience of specialists in use of this group of drugs. Treatment with biological drugs from the group of TNF-alpha inhibitors, including adalimumab, can be carried out in outpatient conditions, also in open treatment, outside of therapeutic programs. The eligibility and subsequent monitoring scheme for adalimumab treatment in the outpatient setting should be based on data from the patient’s medical history, provisions of current clinical guidelines, and the summary of product characteristics. According to its registration, adalimumab may be used in adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy. This provision allows adalimumab to be used both as a first-line generic treatment and after failure (or intolerance) of treatment with another systemic therapy (e.g., methotrexate, cyclosporine, or PUVA).

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Dermatology Review. 2020; 107(2): 92–108.
  2. Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2. Dermatology Review. 2020; 107(2): 110–137.
  3. Charakterystyka Produktu Leczniczego Hyrimoz 06.2021.
  4. Amatore F, Villani AP, Tauber M, et al. Groupe de recherche sur le psoriasis de la Société française de dermatologie, Groupe de recherche sur le psoriasis de la Société française de dermatologie, Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019; 33(3): 464–483.
  5. Menter A, Thaçi D, Wu JJ, et al. Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatol Ther (Heidelb). 2017; 7(3): 365–381.
  6. Blauvelt A, Lacour JP, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018; 179(3): 623–631.